Center for Gastrointestinal Research, Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute and Charles A Sammons Cancer Center, Baylor Research Institute and Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas, USA.
Department of Internal Medicine, Division of Gastroenterology, Baylor Scott & White Research Institute and Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas, USA.
Sci Rep. 2017 Apr 11;7(1):814. doi: 10.1038/s41598-017-00812-6.
Turmeric has been used as a medicinal herb for thousands of years for treatment of various disorders. Although curcumin is the most studied active constituents of turmeric, accumulating evidence suggests that other components of turmeric have additional anti-inflammatory and anti-tumorigenic properties. Herein, we investigated anti-inflammatory efficacy and associated gene expression alterations of a specific, curcumin preparation containing essential turmeric oils (ETO-curcumin) in comparison to standard curcumin at three specific doses (0, 5, 25 or 50 mg/kg), in an animal model of dextran sodium sulfate (DSS)-induced colitis. The present study showed that both ETO and standard curcumin treatments provided protection against DSS-induced inflammation. However, ETO-curcumin improved disease activity index (DAI) dose-dependently, while the anti-inflammatory efficacy of standard curcumin remained constant, suggesting that ETO-curcumin may provide superior anti-inflammatory efficacy compared to standard curcumin. Gene expression analysis revealed that anti-inflammatory cytokines including IL-10 and IL-11 as well as FOXP3 were upregulated in the colon by ETO-curcumin. Collectively, these findings suggest that the combined treatment of curcumin and essential turmeric oils provides superior protection from DSS-induced colitis than curcumin alone, highlighting the anti-inflammatory potential of turmeric.
姜黄作为一种药用植物，已经有几千年的历史，用于治疗各种疾病。尽管姜黄素是姜黄中研究最多的活性成分，但越来越多的证据表明，姜黄的其他成分具有额外的抗炎和抗肿瘤特性。在此，我们研究了一种特定的姜黄素制剂，其中含有必需的姜黄油（ETO-姜黄素），与标准姜黄素（在三个特定剂量 0、5、25 或 50mg/kg）相比，在葡聚糖硫酸钠（DSS）诱导的结肠炎动物模型中的抗炎疗效和相关基因表达变化。本研究表明，ETO 和标准姜黄素治疗均可预防 DSS 诱导的炎症。然而，ETO-姜黄素可剂量依赖性地改善疾病活动指数（DAI），而标准姜黄素的抗炎疗效保持不变，这表明 ETO-姜黄素可能比标准姜黄素具有更好的抗炎疗效。基因表达分析显示，ETO-姜黄素可上调结肠中的抗炎细胞因子，包括 IL-10 和 IL-11 以及 FOXP3。综上所述，这些发现表明，姜黄和必需的姜黄油联合治疗可提供比单独使用姜黄素更好的 DSS 诱导结肠炎保护作用，突出了姜黄的抗炎潜力。
